Praxis Precision Medicines, Inc.
A biopharmaceutical company developing treatments for brain disorders like epilepsy and essential tremor, using two platforms—Cerebrum for small-molecule drugs and Solidus for antisense oligonucleotide therapies. Its lead candidates include ulixacaltamide for essential tremor and seizure-fighting drugs like relutrigine. Founded in 2015 as EpiPM Therapeutics, it took its name from the Greek "praxis," meaning "to do"—turning scientific theory into practical treatment.
Sold 446.5K
Sold 313.9K
Granted 22.0K
Granted 156.5K · Bought 107.0K
Granted 26.6K
Granted 68.9K · Bought 21.9K
Granted 9.7K
Granted 91.3K · Bought 7.5K · Sold 33.4K
Granted 13.6K · Bought 75.0K
Granted 13.0K · Bought 14.5K · Sold 11.6K
Granted 40.2K · Bought 3.0K · Sold 18.8K
Granted 1.4K
Granted 2.5K
Granted 2.5K
Granted 1.4K
Granted 1.4K
Granted 1.4K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| BSOF Parallel Master Fund L.P. +8 co-filers10% owner · 3 transactions | 0% | 10.23Mas of Oct 2021 | — | — | 446.5K |
| Atchinson Robert +2 co-filers10% owner · 10 transactions | — | 4.45M | — | — | 313.9K |
| Ravina BernardChief Medical Officer · 2 transactions | +23.5% | 99.5Kas of Feb 2022 | 22.0K | — | — |
| Souza MarcioChief Executive Officer, Director · 20 transactions | — | 79.6K | 156.5K | 107.0K | — |
| Sweeny NicoleChief Commercial Officer · 5 transactions | +129.9% | 38.6Kas of Feb 2023 | 26.6K | — | — |
| Kelly Timothy EdwinChief Financial Officer · 22 transactions | — | 31.2K | 68.9K | 21.9K | — |
| Sniecinski MeganChief Operating Officer · 4 transactions | — | 28.7K | 9.7K | — | — |
| Nemiroff AlexGeneral Counsel and Secretary · 31 transactions | +109.8% | 26.0K | 91.3K | 7.5K | 33.4K |
| Mitchell Dean JDirector · 6 transactions | — | 18.6K | 13.6K | 75.0K | — |
| DeSimone JillDirector · 16 transactions | — | 13.8K | 13.0K | 14.5K | 11.6K |
| Mastrocola LaurenPrincipal Accounting Officer · 30 transactions | -33.5% | 13.6K | 40.2K | 3.0K | 18.8K |
| Young William DDirector · 1 transaction | -88.5% | 3.3K | 1.4K | — | — |
| Arbuckle Stuart ADirector · 3 transactions | — | 2.5K | 2.5K | — | — |
| Kindler Jeffrey BDirector · 3 transactions | — | 2.5K | 2.5K | — | — |
| Norden GregoryDirector · 1 transaction | -44.8% | 1.6K | 1.4K | — | — |
| Chodakewitz JeffreyDirector · 1 transaction | — | 1.4K | 1.4K | — | — |
| Cudkowicz Merit EsterDirector · 1 transaction | — | 1.4K | 1.4K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: -595.3K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.